CD96 and breast cancer: To validate these clinical findings in vitro, we enriched the BCSC fraction in BC cell lines with low basal CD96 levels (MCF‐7 and SKBR3) on ultra‐low adhesion plates.[22, 23] Western blot analysis revealed that the CD96 protein levels were significantly increased in BCSCs compared to those in adherent BC cells (Figure S2A, Supporting Information).